Skip to main content
PLOS One logoLink to PLOS One
. 2021 Mar 3;16(3):e0241156. doi: 10.1371/journal.pone.0241156

A systematic review and meta-analysis for association of Helicobacter pylori colonization and celiac disease

Fazel Isapanah Amlashi 1, Zahra Norouzi 1, Ahmad Sohrabi 2,3, Hesamaddin Shirzad-Aski 2,*, Alireza Norouzi 1, Ali Ashkbari 1, Naghme Gilani 1, Seyed Alireza Fatemi 1, Sima Besharat 1,2,*
Editor: Endi Lanza Galvão4
PMCID: PMC7928511  PMID: 33657108

Abstract

Background and objectives

Based on some previous observational studies, there is a theory that suggests a potential relationship between Helicobacter pylori (H. pylori) colonization and celiac disease (CeD); however, the type of this relationship is still controversial. Therefore, we aimed to conduct a systematic review and meta-analysis to explore all related primary studies to find any possible association between CeD and human H. pylori colonization.

Data sources

Studies were systematically searched and collected from four databases and different types of gray literature to cover all available evidence. After screening, the quality and risk of bias assessment of the selected articles were evaluated.

Synthesis methods

Meta-analysis calculated pooled odds ratio (OR) on the extracted data. Furthermore, heterogeneity, sensitivity, subgroups, and publication bias analyses were assessed.

Results

Twenty-six studies were included in this systematic review, with a total of 6001 cases and 135512 control people. The results of meta-analysis on 26 studies showed a significant and negative association between H. pylori colonization and CeD (pooled OR = 0.56; 95% CI = 0.45–0.70; P < 0.001), with no publication bias (P = 0.825). The L’Abbé plots also showed a trend of having more H. pylori colonization in the control group. Among subgroups, ORs were notably different only when the data were stratified by continents or risk of bias; however, subgroup analysis could not determine the source of heterogeneity.

Conclusions

According to the meta-analysis, this negative association might imply a mild protective role of H. pylori against celiac disease. Although this negative association is not strong, it is statistically significant and should be further considered. Further investigations in both molecular and clinic fields with proper methodology and more detailed information are needed to discover more evidence and underlying mechanisms to clear the interactive aspects of H. pylori colonization in CeD patients.

Systematic review registration number (PROSPERO)

CRD42020167730 https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=167730.

Introduction

Celiac disease (CeD) is an inflammatory autoimmune disease with small intestine enteropathy disorder triggered by gluten ingestion [1]. CeD is a multifactorial disease that has risen from the interaction between gluten and immune, genetic, and environmental factors and can be diagnosed at any age [2]. Serological prevalence of CeD is around 1% in the general population; with a slight difference between Western and Eastern countries (1% vs. 1.6%) [35]. The incidence and prevalence of CeD have increased over the years that could be due to better diagnostic tools, screening of high-risk individuals, and general awareness or due to the real increasing rate of the disease based on the alteration of lifestyle or gut microbiota [1,6].

H. pylori is one of the most common chronic bacterial infections worldwide, it can cause significant gastroduodenal diseases [7]. The infection affects up to 90% of the population in developing countries and around 40% in developed countries. Generally, half of the global population can have H. pylori colonization [8]. There are controversies about the probable relation between H. pylori colonization and autoimmune diseases [9]. H. pylori can modulate some immune responses and play a protective role against some other diseases such as inflammatory bowel disease (IBD) [10]. Otherwise, in genetically predisposed persons, H. pylori can influence immune responses and cause microscopic duodenal inflammation and can be related to more severe damage associated with some gastrointestinal diseases [1114]. In this regard, some studies reported no relationship between H. pylori and CeD [1517]; whereas, others stated that H. pylori can protect against CD [14,18]. There are different hypotheses and justification about the mechanism of interaction between H. pylori and CeD.

The hygiene hypothesis is one of the explanations for the protective role of H. pylori infection against CeD and claims that lower exposure to some infectious agents in childhood leads to an increase in the risk of autoimmune diseases such as asthma, IBD, allergic rhinitis, and eczema [13,1922]. Different mechanisms are suggested for this hypothesis. One of them is T helper (Th) 1/Th2 deviation, which suggests that the presence of infection causes the balance of Th1/Th2 to move towards an immunosuppression state. T regulatory (Treg) lymphocytes might be induced or augmented (a phenomenon called bystander suppression) due to infection [19,22,23]. Also, there are more suggested mechanisms for this hypothesis, such as antigenic competition/homeostasis, non-antigenic ligands, and gene-environment interaction [19,22,23].

Another hypothesis is the protective role of H. pylori on the modification of gluten digested by proteases secretion, and increase of the pH of the gastric lumen, which reduces the immunogenicity of gluten [13,14,19,2224]. Some studies suggested another theory and supported the idea that a specific virulence factor, such as CagA in H. pylori, may give the bacterium a protective role in CeD. This function of CagA may be due to the association with Treg cells in the immunoregulation mechanism [17,2426].

The fourth important theory is related to empirical antibiotic treatment in patients suspicious to gastrointestinal bacterial overgrowth, which was eventually diagnosed as CeD. This treatment may lead to the unintentional removal of H. pylori [2729].

Otherwise, some researchers claimed that H. pylori may be involved in the development of CeD. Mooney et al. mentioned that maybe H. pylori acts as an environmental trigger for CeD, as observed in Campylobacter infection, in a study of the US military [21,30]. However, the mechanism of this act is not properly defined. Furthermore, a study at Colombia University showed increased intraepithelial lymphocytes in the duodenal mucosa in patients with H. pylori infection that could be reversed by the eradication of H. pylori [31].

Up to now and based on our search, no systematic review and meta-analysis have been conducted about this subject. Due to the inconsistency of the previous primary studies, we aimed to prepare a systematic review to scrutinize any possible association between H. pylori colonization and CeD.

Materials and methods

Eligibility criteria

The design of the present study was based on the methodology of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline [32]. This review is registered in the international prospective register of systematic reviews (PROSPERO) with registration number CRD42020167730 (Available: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=167730).

Definition

Celiac disease

CeD patients were defined if they were positive for CeD-specific antibodies (comprise autoantibodies against TG2, including endomysial antibodies (EMA), and antibodies against deamidated forms of gliadin peptides (DGP)), associated with biopsy-proven histopathology or positive genetic tests: HLA-DQ2 or HLA-DQ8 haplotypes in the primary studies.

Controls

Based on the definitions in the primary studies, controls consisted of those apparently healthy people or celiac disease was ruled out through negative serology/biopsy.

Inclusion/Exclusion criteria

Inclusion criteria included: 1) Case-control, cross-sectional, suitable cohort, and brief-report studies that contain evidence about the relationship between H. pylori and CeD, 2) Human clinical study, 3) Having at least one parameter of the relative risk effect sizes such as risk ratio (RR), odds ratio (OR), and hazard ratio (HR) or can be calculated based on the information of H. pylori status in both case and control groups.

The status of H. pylori should be detected by urea breath test (UBT), rapid urease test (RUT), culture, enzyme-linked immunosorbent assay (ELISA), histology, immunohistochemistry (IHC), and Polymerase chain reaction (PCR) methods. Furthermore, the CeD should be confirmed by endoscopy and biopsy ± serology tests and/or HLA DQ2/DQ8 genotyping. Articles without any of this information were excluded from further analysis.

Sources and search strategy

All relevant articles, published from 1990 to the end of the second month of 2021 were collected from the electronic database of PubMed, ProQuest, Scopus, and Web of Science. The ProQuest database was also reviewed for related dissertations, manually. Other related protocols were manually searched in PROSPERO. Besides, to expand the scope of the search and find any additional studies, we reviewed the different types of grey literatures such as meeting and conference abstracts for relevant articles (including Digestive Disease Week® (DDW), United European Gastroenterology (UEG), and American College of Gastroenterology). Moreover, we searched manually some key journals in the CeD and H. pylori fields, including "World Journal of Gastroenterology", "Journal of Pediatric Gastroenterology and Nutrition", "Gut", "Gastroenterology", and "Helicobacter". In the end, we performed a manual search in the references of the selected articles. We did not impose geographical or linguistic restrictions on our search, and non-English studies with English abstracts were also included.

The Medical subject heading (MeSH) database was used to find various terms of CeD and H. pylori. Two main keywords were “Helicobacter pylori” and “Celiac”. For better searching in the databases, we made syntaxes from a combination of free-text method, MeSH terms, the keywords, and Boolean operators (AND/OR/NOT). Moreover, calculating NNR (number need to read) helped us in evaluating the output of syntax and dedicating. The following syntax was applied in PubMed and adjusted for each search engine based on its search guidelines (Celiac OR “Celiac disease” OR Coeliac OR “Coeliac disease” OR (Disease AND Celiac) OR (Disease AND Coeliac) OR “Gluten Enteropathy” OR (Enteropathy AND Gluten) OR "Gluten Enteropathies" OR (Enteropathies AND Gluten) OR “Gluten-Sensitive Enteropathy” OR (Enteropathy AND Gluten-Sensitive) OR “Gluten-Sensitive Enteropathies” OR (Enteropathies AND Gluten-Sensitive) OR (Sprue AND Celiac) OR (Sprue AND Coeliac) OR (Sprue AND Nontropical) OR “Nontropical Sprue” OR “Celiac Sprue” OR “Coeliac Sprue” OR “Sprue” “Endemic Sprue” OR “Gluten Intolerance”) AND ("Helicobacter pylori" OR "Campylobacter pylori" OR "Campylobacter pyloridis" OR "Campylobacter pyloris" OR "Helicobacter nemestrinae" OR "Helicobacter infection" OR "HP infection" OR "HP infections" OR "Helicobacter infections" OR "Helicobacter colonization" OR "HP colonization" OR "Helicobacter colonization" OR "H Pylori" OR "enterohepatic Helicobacter" OR "EHS" OR "Helicobacter") AND 1990/01/01:2021/02/20[dp].

The search outputs were exported into the Endnote software (Version X7; Thompson Reuters Corporation, Toronto, ON, Canada) to remove any duplicate and screen articles. The first step of screening for determining the eligible primary articles was done based on the titles and abstracts. Two independent reviewers (A.A. and A.F.) evaluated the selected full-text articles and separately classified them into three relevant, irrelevant, and unsure groups, based on the eligibility criteria. Any discrepancy was supervised by a third reviewer (S.B.) and resolved via a consensus. If there was still a doubt in the selection of a study, the whole team made the final decision.

Quality and risk of bias assessment

The quality and risk of bias assessment of the selected articles were independently evaluated by two reviewers (Z.N. and N.G.), using the standard checklist of the Newcastle-Ottawa Scale (NOS) form [33]. The studies were classified into three poor, fair, and good categories based on getting a score between zero and eight in the selection, comparability, and outcome/exposure domains based on the standard guideline. Consensus and the opinion of the third reviewer (S.B) resolved any disagreements between the two reviewers.

Data extraction

Two authors (Z.N, F.A) independently performed data extraction from each paper based on a defined protocol. The data were divided into three categories and included 1) General information: the first author’s names, year of publication, journal names, country, and region; 2) The risk of bias assessment; 3) Study setting: study design, study duration, sample size and total population recruited in each study, inclusion and exclusion criteria, age group and age range, sex, the definition of CeD, source of the data, diagnostic methods, OR and 95% CI, and the ethical approval. In cases of any missing or additional necessary data, we further sent an e-mail to each author, in charge of the related study.

Data synthesis and analysis

We used the R software environment, version 4.0.2, and the “meta” package to calculate pooled OR and 95% CIs for each study. Based on the methodological heterogeneity between the studies, the random-effect model (REM) was used for the combination method. The size of the combined effect was calculated and displayed in a forest plot. The standard chi-square test (Q Cochrane test) and I2 scale evaluated the heterogeneity between studies. Combinations with an I2 scale equal or more than 70% assumed as a severe heterogeneity. In addition, a Drapery plot was drawn to show the P-value functions for the included studies, as well as pooled estimates, and to provide two-sided confidence intervals for all possible alpha levels (confidence interval function) [34,35]. For finding the cause(s) of heterogeneity, subgroup and sensitivity analyses were used. The studies were stratified based on each factor, including the median of publication year, overall age group of the participants, continent and regions of the studies, H. pylori detection method, the risk of bias assessment, as well as sampling quality. In the last subgroup, sampling, the articles were categorized into two groups (I) “Appropriate sampling” or (II) “Not appropriate sampling” groups. The studies were located in the “Not appropriate sampling” group, if the number of participants in each case and control group was less or equal than 50 people or the ratio of control to the cases was more than four times or less than 90%.

The funnel chart, followed by Begg’s test analyzed possible publication bias. Baujat and L’Abbé plots were used to show the effect of each study on the heterogeneity and overall influence of the results [3638]. Finally, a one-out remove method was used to detect the influence of each study on the overall pooled OR.

Results

Search results

In total, the general searching step obtained 1732 papers. After removing duplicates, 1106 studies were screened, based on their titles and abstracts. Among them, 1014 articles were excluded due to not meeting the inclusion criteria. Therefore, the full-texts of 92 remained articles were completely evaluated. Finally, 26 studies were included in the systematic review and also meta-analysis (kappa (κ) = 0.84) [11,1318,21,2427,3952], and the others were excluded due to a reason mentioned in Fig 1 (Fig 1). In the end, there was no suitable cohort study in the included studies.

Fig 1. Flow diagram of literature search, screening, and selection of studies for review and meta-analysis.

Fig 1

Characteristics of the included articles

The designs of all the included studies were case-control, with a total of 6001 cases and 135512 control people. Among the studies Lebwohl et al. had the highest study population with 130308 participants (included 2689 cases and 127619 controls) [14]. Most studies were from Turkey (N = 6) [1518,51,52] and Italy (N = 5) [11,27,44,45,48]. Some studies had been performed only on children [13,1517,21,44,47,51,52] or adults [18,25,27,39,43,45,48], the others evaluated both age groups [11,14,42,49,50]. Table 1 shows the details of the included articles. The NOS assessment showed that only 19.2% of the studies had good quality.

Table 1. Main characteristics of the included studies in the meta-analysis on the Helicobacter pylori infection and celiac disease (CeD).

First author Year Journal title Country Definition of CeD Risk of bias assessment Case-number Control—number Laboratory tests of H. pylori
Karttunen 1990 Journal of Clinical Pathology Finland Registry Fc 27 27 IHCf
Crabtree 1992 Journal of Clinical Pathology England Endoscopy + Serology + Positive response to GFDb Pd 99 250 ELISAg
Feeley 1998 Journal of Clinical Pathology Ireland Registry F 70 70 IHC
Diamantti 1998 Intestinal Disorders (poster) Argentina Endoscopy P 108 113 IHC
Diamantti 1999 The American Journal of Gastroenterology Argentina Endoscopy + Serology + Positive response to GFD P 104 75 IHC
Luzza 1999 Journal of Pediatric Gastroenterology and Nutrition Italy Endoscopy+ Positive response to GFD Ge 81 81 IHC + RUTh + ELISA
Konturek 2000 The American Journal of Gastroenterology Germany Endoscopy + Serology F 91 40 ELISA
Ciacci 2000 European Journal of Gastroenterology and Hepatology Italy Endoscopy P 187 76 IHC + ELISA
Dettori 2001 Digestive and Liver Disease (Poster) Italy Endoscopy + Serology G 152 306 UBTi + IHC
Aydogdu 2008 Scandinavian Journal of Gastroenterology Turkey Endoscopy + Serology P 96 235 IHC
Rostami-Nejad 2009 Revista espanola de enfermedades digestivas Iran Endoscopy + Serology P 28 422 IHC
Rostami-Nejad 2011 Archives of Iranian Medicine Iran Endoscopy + Serology P 24 226 IHC
Lebwohl 2013 American Journal of Epidemiology American Endoscopy F 2689 127619 IHC
Simondi 2015 Clinics and Research in Hepatology and Gastroenterology Italy Endoscopy + Serology + HLA DQ2/DQ8 genotyping F 73 404 UBT + IHC
Jozefczuk 2015 European Review for Medical and Pharmacological Science Poland Endoscopy + Serology F 74 296 UBT
Lasa 2015 Arquivos de Gastroenterologia Argentina Endoscopy + Serology G 72 240 IHC
Jozefczuk 2016 European Review for Medical and Pharmacological Science Poland Endoscopy + Serology F 76 84 UBT + ELISA
Uyanikoglu 2016 Euroasian Journal of Hepato-Gastroenterology Turkey Endoscopy F 31 592 IHC
Narang 2017 Journal of Gastroenterology and Hepatology India Endoscopy + Serology + Positive response to GFD G 324 322 IHC + RUT
Broide 2017 AGA abstracts Germany Endoscopy + Serology F 50 50 UBT + IHC
Lucero 2017 Frontiers in Cellular and Infection Microbiology Chile Endoscopy + Serology + HLA DQ2/DQ8 genotyping G 66 50 IHC + RUT
Agin 2019 Archives of Medical Science Turkey Endoscopy + Serology P 256 1012 IHC
Cam 2018 EHMSG a Turkey Endoscopy P 141 150 UBT + IHC
Dore 2018 Helicobacter Italy Endoscopy + HLA DQ2/DQ8 genotyping F 270 127 UBT + IHC
Bayrak 2020 Helicobacter Turkey Endoscopy + Serology F 482 2060 UBT + IHC
Bayrak 2021 Digestive Diseases Turkey Endoscopy + Serology F 278 505 UBT + IHC

aXXXIst International Workshop on Helicobacter & Microbiota in Inflammation & Cancer;

bgluten-free diet;

cFair;

dPoor;

eGood;

fImmunohistochemistry;

gEnzyme-linked immunosorbent assay;

hRapid Urease Test;

iUrease Breath Test.

Association between H. pylori and CeD

By analyzing a combination of 26 studies that addressed the association between H. pylori colonization and CeD, a negative association was found (pooled OR = 0.56; 95% CI = 0.45 − 0.70; P ≤ 0.001). The REM and Chi-squared method showed a significant statistical heterogeneity between the studies I2 = 81%, P ≤ 0.001, and X2 = 130, P ≤ 0.001, respectively (Fig 2).

Fig 2. The Forest plot of the meta-analysis on the association of the Helicobacter pylori and celiac disease.

Fig 2

The random-effects model was used to calculate pooled ORs with 95% CI. CI, Confidence interval; OR, Odds ratio.

Fig 3A shows a Drapery plot, presenting that the estimated effect is less than 1 in the majority of studies, similarly as shown in the Funnel plot. As the horizontal dashed lines show the CIs for common alpha levels (0.1, 0.05, 0.01, 0.001), at any level of prediction interval (90, 95, 99, 99.9%), the main triangle line (the red-bolded line in the online version) did not intersect the null effect line (Incidence Rate Ratio (IRR) = 1). According to the results of the Funnel plot and Begg’s tests, there was no significant publication bias (P = 0.825, Fig 3B). The Baujat plot (Fig 3C) showed that the study of Narang et al. contributes more than the other studies on the overall heterogeneity and influences the pooled effect size. The L’Abbé plots (Fig 3D) also showed a trend of having more H. pylori colonization in the control group.

Fig 3.

Fig 3

(A) The drapery plot shows p-value functions for the included studies as well as pooled estimates and the two-sided confidence intervals for all possible alpha levels (confidence interval function). Each number represents a study. The red-bolded line (in the online version; bold line in the printed version) indicates the range of pooled odds ratio (OR) in each alpha level. (B) The Funnel chart shows no significant publication bias, as all studies are in a symmetric scheme. (C) The Baujat plot shows the effect of each study on the heterogeneity and overall influence of the results. As can be seen in the graph, the study of Narang et al. contributes more than the other studies to the overall heterogeneity. Each circle represents a study. (D) The L’Abbé plot shows more positive results for H. pylori colonization in the control group. The diagonal (x = y) oblique line represents the odds ratio (OR) equal to one. The dashed line indicates the OR of the studies. The size of each circle indicates the assigned random weight of each study. As the picture shows, most studies show an OR of less than one.

Subgroup and sensitivity analyses

The heterogeneity between studies was evaluated by multiple subgroup analyses in the six subgroups. Based on the continents of the studies, there were few studies in Asia, which made the results unreliable for the statistical analysis [13,49,50]. Europe has a higher OR (OR = 0.63, 95% CI = 0.49 − 0.82) than America (OR = 0.55, 95% CI = 0.40 − 0.76) and Asia (OR = 0.23, 95% CI = 0.10 − 0.52). However, further evaluation is needed due to the low rate of studies, especially in Asia. Other subgroups could not determine the source of heterogeneity (Table 2).

Table 2. Different subgroup analysis by stratifying the data.

Subgroups Na of articles N of cases N of controls ORb P-Value Chi-Square I2 Tau2
Combination of all studies 26 6001 135512 0.56 <0.001 130.80 81 0.2452
Year Before 2014 13 3756 129540 0.56 0.001 32.47 63 0.1350
2014 & after 2014 13 2245 5972 0.56 <0.001 98.17 88 0.3804
Overall age Children (Less than 18) 10 1910 4875 0.57 <0.001 92.64 90 0.4505
Adult (More than 18) 9 894 1919 0.60 0.004 22.59 65 0.1785
All age 7 3197 128718 0.52 0.08 11.41 47 0.0734
Continent Europe 18 2586 6445 0.63 <0.001 75.43 77 0.2138
America 5 3039 128097 0.55 0.15 6.81 41 0.0516
Asia 3 376 970 0.23 0.06 5.67 65 0.3481
Sampling Appropriate sampling 14 1929 3794 0.57 <0.001 97.94 87 0.4459
Inappropriate sampling 12 4072 131718 0.55 0.001 30.2 64 0.0983
H. Pylori detection tests IHCc & ELISAd 20 5307 134275 0.58 <0.001 77.88 76 0.1598
UBTe & RUTf 6 694 1234 0.52 <0.001 45.88 89 0.9442
Risk of bias Poor 9 1043 2559 0.72 0.009 20.23 60.0 0.1231
Fair 12 4263 131954 0.55 0.001 31 65.0 0.0873
Good 5 695 999 0.39 <0.001 31.84 87.0 0.6152

aNumber;

bOdds ratio;

cImmunohistochemistry;

dEnzyme-linked immunosorbent assay;

eUrease Breath Test;

fRapid Urease Test.

Based on the one-out removed method, the removal of any of the studies could not significantly affect the pooled results. The sensitivity analysis was used to find possible outlier studies with more influence on the results. In this regard, the studies with poor design or not appropriate sampling (the most influential factors in the methodology) were omitted, and the overall effect size and level of heterogeneity were recalculated. The overall OR decreased from 0.56 (95% CI = 0.45 − 0.76) to 0.40 (95% CI: 0.26 − 0.62) but no change in the heterogeneity was observed. The results of the sensitivity analysis confirmed that the correct methodology was significantly associated with a lower amount of overall OR (Table 3).

Table 3. Subgroups sensitivity analysis.

Models Subgroups Na of articles N of cases N of controls ORb P-Value Chi-Square I2 Tau2
All studies 26 6001 135512 0.56 <0.001 130.80 81 0.2452
Without “poor” quality studies 17 4958 132953 0.49 <0.001 75.27 79 0.1973
Europe 13 1807 4722 0.57 <0.001 38.58 67 0.1433
America 3 2827 127909 0.47 0.40 1.84 0 0
Asia 1 324 322 0.13 NA NA NA NA
Appropriate sampling 9 1229 2034 0.40 <0.001 38.76 79 0.3288
Inappropriate sampling 8 3729 130919 0.62 <0.001 26.81 74 0.1195
Without “not appropriate sampling” studies 14 1929 3794 0.54 <0.001 97.94 87 0.4459
Poor 5 700 1760 0.98 0.98 0.4 0 0
Fair 5 600 1085 0.45 0.32 4.67 14 0.0200
Good 4 629 949 0.34 <0.001 26.14 89 0.6170
Europe 11 1425 3119 0.66 <0.001 37.91 74 0.1925
America 2 180 353 0.56 0.04 4.33 77 0.3658
Asia 1 324 322 0.13 NA NA NA NA
Without “poor” quality and “not appropriate sampling” studies 9 1229 2034 0.40 <0.001 38.76 79 0.3288
Fair 5 600 1085 0.45 0.32 4.67 14 0.0200
Good 4 629 949 0.34 <0.001 26.14 89 0.6170
Europe 7 833 1472 0.48 0.11 10.3 42 0.0691
America 1 72 240 0.33 NA NA NA NA
Asia 1 324 322 0.13 NA NA NA NA

anumber;

bodds ratio;

†The bolded items show a statistical difference in OR of region subgroup.

Discussion

Most information about the relationship between H. pylori colonization and CeD is inferred from case-control studies and more prospective cohort and /or systematic review are needed to provide the strongest evidence about this association. In this regard, the present study is the first systematic review and meta-analysis that aimed to clarify any possible association between H. pylori colonization and CeD. The meta-analysis showed a mild negative relationship between H. pylori and CeD, and confirmed the findings of some previous studies, showing H. pylori was significantly more prevalent in apparently healthy people than celiac patients [11,13,14].

The protective effect of H. pylori on some allergic and atopic diseases and other inflammatory diseases could be considered as starting point of the debates about the association between CeD and H. pylori [10,17,18,21].

For clearing the possible protective effect of the immune-suppressive mechanisms of H. pylori on CeD, the first step is the specification of the chronological order of CeD and H. pylori colonization. As there was not any cohort study on this subject, there is no strong evidence to show a cause and effect relationship between these two and a protective effect of H. pylori on the occurrence of CeD. Therefore, conducting a cohort study should be considered as a top priority in further investigations of this subject.

Beyond our subgroup analyses, there are more interactive aspects of the pathophysiology of CeD and pathogenesis of H. pylori that could help us to explore the causes of the heterogeneity. Both CeD and H. pylori cause inflammation and immune response in the GI tract and also H. pylori could escape human immune defense via different mechanisms that suppress both innate and adaptive immune response [53]. H. pylori can evade host immune response via activating signaling pathway, sustain intracellularly in macrophages and induction of apoptosis, inhibition of leukocyte migration, and producing arginase enzyme.

Recent studies reported that Vacuolating cytotoxin (VacA) of H. pylori has an immunomodulatory role by inhibiting integrin-linked kinase (ILK) [54]. VacA also intervenes with the antigen presentation of MHC class II [55] and it directly suppresses T-cells rather than antigen presenting cells (APC) [56]. It is possible that these suppressive mechanisms produced by H. pylori, affect the autoimmune response to gluten and reduce the level of gluten enteropathy in CeD. Considering the notion of a balance between immune suppressive mechanisms of H. pylori and autoimmune response in CeD, it seems more probable to observe a protective effect against autoimmune response among patients who are infected with a type of H. pylori.

In this systematic review and meta-analysis related to the association of H. pylori colonization and CeD, our search strategy prepared a comprehensive source of articles that contains any study with related evidence. Subgroup and sensitivity analyses showed that two factors (sampling method and the quality of article) could be more effective and important for case-control studies and it is better to be addressed in future studies. In addition, the analyses showed that this protective effect of H. pylori on CeD was more observed in Asian countries. After removing the studies with poor quality and non-appropriate sampling, the pooled OR was still statistically lower in a study from Asia, in comparison to both studies from Europe and America. However, heterogeneity was still more than 70% in this continent subgroup. Unfortunately, after removing the studies in sensitivity analysis, only one study from Asia remained, and the obtained results could not completely determine the source of heterogeneity. Here, we suggest conducting well-designed studies in Asia, especially in the East Asian population to clarify the role of ethnicity in the association of H. pylori colonization and CeD.

The present study had some limitations. First, just a few numbers of the selected articles had a good-quality method and many of them did not consider many confounding factors in the design of the study such as March type, the severity of celiac, H. pylori virulence, and IgA deficiency that could affect the results. Second, based on the results, the heterogeneity of outcomes was high, and the subgroup analysis could not recognize the source of it completely. Third, most of the studies were conducted in Western countries, especially in Turkey and Italy. There was no article from Africa. Moreover, only three articles reported the situation in Asia. Studying other ethnicities can be a suitable target for further investigations.

Conclusion

The meta-analysis of 26 clinical studies included 6001 CeD patients from both children and adult age-groups showed a mild protective role of H. pylori against celiac disease. The main obstacle on the way of placing the role of H. pylori in CeD under scrutiny is the shortage of accurate details in the clinical studies. To clear the relationship between H. pylori and CeD, it is suggested to implement cohort studies and also further primary studies with good methodology. Extending the scope of study about this subject to the molecular context may prepare more answers to the current controversies.

Supporting information

S1 Checklist

(DOC)

S1 File

(DOCX)

Data Availability

The data underlying the results presented in the study are available from supporting information files.

Funding Statement

Golestan University of Medical Sciences, Gorgan, Iran has supported this study (grant number: GOUMS111462). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Lebwohl B, Sanders DS, Green PHR. Coeliac disease. Lancet. 2018;391: 70–81. 10.1016/S0140-6736(17)31796-8 [DOI] [PubMed] [Google Scholar]
  • 2.Green PHR, Cellier C. Celiac disease. N Engl J Med. 2007;357: 1731–1743. 10.1056/NEJMra071600 [DOI] [PubMed] [Google Scholar]
  • 3.Parzanese I, Qehajaj D, Patrinicola F, Aralica M, Chiriva-Internati M, Stifter S, et al. Celiac disease: From pathophysiology to treatment. World J Gastrointest Pathophysiol. 2017;8: 27. 10.4291/wjgp.v8.i2.27 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Singh P, Arora S, Singh A, Strand TA, Makharia GK. Prevalence of celiac disease in Asia: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31: 1095–1101. 10.1111/jgh.13270 [DOI] [PubMed] [Google Scholar]
  • 5.Al-Toma A, Volta U, Auricchio R, Castillejo G, Sanders DS, Cellier C, et al. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten‐related disorders. United Eur Gastroenterol J. 2019;7: 583–613. 10.1177/2050640619844125 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Lebwohl B, Rubio-Tapia A. Epidemiology, Presentation, and Diagnosis of Celiac Disease. Gastroenterology. 2021;160: 63–75. 10.1053/j.gastro.2020.06.098 [DOI] [PubMed] [Google Scholar]
  • 7.Klitorakis I, Stanciu C. Prevalence of Helicobacter pylori infection in patients with gastroesophageal reflux disease. Rev medico-chirurgicalǎ a Soc Medici şi Nat din Iaşi. 2010;114: 80–84. [PubMed] [Google Scholar]
  • 8.Tonkic A, Tonkic M, Lehours P, Mégraud F. Epidemiology and Diagnosis of Helicobacter pylori Infection. Helicobacter. 2012;17: 1–8. 10.1111/j.1523-5378.2012.00975.x [DOI] [PubMed] [Google Scholar]
  • 9.Smyk DS, Koutsoumpas AL, Mytilinaiou MG, Rigopoulou EI, Sakkas LI, Bogdanos DP. Helicobacter pylori and autoimmune disease: Cause or bystander. World J Gastroenterol. 2014;20: 613–629. 10.3748/wjg.v20.i3.613 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Shirzad-Aski H, Besharat S, Kienesberger S, Sohrabi A, Roshandel G, Amiriani T, et al. Association Between Helicobacter pylori Colonization and Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2020. 10.1097/MCG.0000000000001415 [DOI] [PubMed] [Google Scholar]
  • 11.Ciacci C, Squillante A, Rendina D, Limauro S, Bencivenga C, Labanca F, et al. Helicobacter pylori infection and peptic disease in coeliac disease. Eur J Gastroenterol Hepatol. 2000;12: 1283–1287. 10.1097/00042737-200012120-00004 [DOI] [PubMed] [Google Scholar]
  • 12.Krigel A, Turner KO, Makharia GK, Green PHR, Genta RM, Lebwohl B. Ethnic variations in duodenal villous atrophy consistent with celiac disease in the United States. Clin Gastroenterol Hepatol. 2016;14: 1105–1111. 10.1016/j.cgh.2016.04.032 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Narang M, Puri AS, Sachdeva S, Singh J, Kumar A, Saran RK. Celiac disease and Helicobacter pylori infection in children: Is there any Association? J Gastroenterol Hepatol. 2017;32: 1178–1182. 10.1111/jgh.13654 [DOI] [PubMed] [Google Scholar]
  • 14.Lebwohl B, Blaser MJ, Ludvigsson JF, Green PHR, Rundle A, Sonnenberg A, et al. Decreased risk of celiac disease in patients with Helicobacter pylori colonization. Am J Epidemiol. 2013;178: 1721–1730. 10.1093/aje/kwt234 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Aydogdu S, Cakir M, Ali Yuksekkaya H, Tumgor G, Baran M, Arikan C, et al. Helicobacter pylori infection in children with celiac disease. Scand J Gastroenterol. 2008;43: 1088–1093. 10.1080/00365520802101846 [DOI] [PubMed] [Google Scholar]
  • 16.Cam S, Ugras M. Children with Celiac disease have less H. pylori gastritis. Helicobacter. Wiley 111 River St, Hoboken 07030–5774, NJ USA; 2018.
  • 17.Agin M, Batun I, Ozdemir S, Doran F, Tumgor G. Prevalence of Helicobacter pylori in Turkish children with celiac disease and its effect on clinical, histopathological, and laboratory parameters. Arch Med Sci AMS. 2019;15: 1475. 10.5114/aoms.2019.83699 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Uyanikoglu A, Dursun H, Yenice N. Is There any Association Between Celiac Disease and Helicobacter pylori? Euroasian J hepato-gastroenterology. 2016;6: 103. 10.5005/jp-journals-10018-1179 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Christen U, von Herrath MG. Infections and autoimmunity—good or bad? J Immunol. 2005;174: 7481–7486. 10.4049/jimmunol.174.12.7481 [DOI] [PubMed] [Google Scholar]
  • 20.Brooks C, Pearce N, Douwes J. The hygiene hypothesis in allergy and asthma: an update. Curr Opin Allergy Clin Immunol. 2013;13: 70–77. 10.1097/ACI.0b013e32835ad0d2 [DOI] [PubMed] [Google Scholar]
  • 21.Jozefczuk J, Bancerz B, Walkowiak M, Glapa A, Nowak J, Piescikowska J, et al. Prevalence of Helicobacter pylori infection in pediatric celiac disease. Age [years]. 2015;6: 3.0. [PubMed] [Google Scholar]
  • 22.Okada H, Kuhn C, Feillet H, Bach J. The ‘hygiene hypothesis’ for autoimmune and allergic diseases: an update. Clin Exp Immunol. 2010;160: 1–9. 10.1111/j.1365-2249.2010.04139.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Bach J-F. The hygiene hypothesis in autoimmunity: the role of pathogens and commensals. Nat Rev Immunol. 2018;18: 105. 10.1038/nri.2017.111 [DOI] [PubMed] [Google Scholar]
  • 24.Lasa J, Zubiaurre I, Dima G, Peralta D, Soifer L. Helicobacter pylori prevalence in patients with celiac disease: results from a cross-sectional study. Arq Gastroenterol. 2015;52: 139–142. 10.1590/S0004-28032015000200012 [DOI] [PubMed] [Google Scholar]
  • 25.Konturek PC, Karczewska E, Dieterich W, Hahn EG, Schuppan D. Increased prevalence of Helicobacter pylori infection in patients with celiac disease. Am J Gastroenterol. 2000;95: 3682. 10.1111/j.1572-0241.2000.03421.x [DOI] [PubMed] [Google Scholar]
  • 26.Lucero Y, Oyarzún A, O’Ryan M, Quera R, Espinosa N, Valenzuela R, et al. Helicobacter pylori cagA+ is associated with milder duodenal histological changes in Chilean celiac patients. Front Cell Infect Microbiol. 2017;7: 376. 10.3389/fcimb.2017.00376 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Simondi D, Ribaldone DG, Bonagura GA, Foi S, Sapone N, Garavagno M, et al. Helicobacter pylori in celiac disease and in duodenal intraepithelial lymphocytosis: active protagonist or innocent bystander? Clin Res Hepatol Gastroenterol. 2015;39: 740–745. 10.1016/j.clinre.2015.03.005 [DOI] [PubMed] [Google Scholar]
  • 28.De Boissieu D, Chaussain M, Badoual J, Raymond J, Dupont C. Small-bowel bacterial overgrowth in children with chronic diarrhea, abdominal pain, or both. J Pediatr. 1996;128: 203–207. 10.1016/s0022-3476(96)70390-6 [DOI] [PubMed] [Google Scholar]
  • 29.Teo M, Chung S, Chitti L, Tran C, Kritas S, Butler R, et al. Small bowel bacterial overgrowth is a common cause of chronic diarrhea. J Gastroenterol Hepatol. 2004;19: 904–909. 10.1111/j.1440-1746.2004.03376.x [DOI] [PubMed] [Google Scholar]
  • 30.Mooney PD, Evans KE, Barrett SM, Arnaout A, Sanders DS. Re:" Decreased risk of celiac disease in patients with Helicobacter pylori colonization". Am J Epidemiol. 2014;179: 1275. [DOI] [PubMed] [Google Scholar]
  • 31.Memeo L, Jhang J, Hibshoosh H, Green PH, Rotterdam H, Bhagat G. Duodenal intraepithelial lymphocytosis with normal villous architecture: common occurrence in H. pylori gastritis. Mod Pathol. 2005;18: 1134–1144. 10.1038/modpathol.3800404 [DOI] [PubMed] [Google Scholar]
  • 32.Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS med. 2009;6: e1000097. 10.1371/journal.pmed.1000097 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Wells G, Shea B, O’connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute. oxford. asp; 2011. [Google Scholar]
  • 34.Birnbaum A. Confidence curves: An omnibus technique for estimation and testing statistical hypotheses. J Am Stat Assoc. 1961;56: 246–249. [Google Scholar]
  • 35.Infanger D, Schmidt‐Trucksäss A. P value functions: An underused method to present research results and to promote quantitative reasoning. Stat Med. 2019;38: 4189–4197. 10.1002/sim.8293 [DOI] [PubMed] [Google Scholar]
  • 36.Deeks JJ. Issues in the selection of a summary statistic for meta‐analysis of clinical trials with binary outcomes. Stat Med. 2002;21: 1575–1600. 10.1002/sim.1188 [DOI] [PubMed] [Google Scholar]
  • 37.L’abbé Ka Detsky As, O’rourke K. Meta-analysis in clinical research. Ann Intern Med. 1987;107: 224–233. 10.7326/0003-4819-107-2-224 [DOI] [PubMed] [Google Scholar]
  • 38.Baujat B, Mahé C, Pignon J, Hill C. A graphical method for exploring heterogeneity in meta‐analyses: application to a meta‐analysis of 65 trials. Stat Med. 2002;21: 2641–2652. 10.1002/sim.1221 [DOI] [PubMed] [Google Scholar]
  • 39.Karttunen T, Niemelä S. Lymphocytic gastritis and coeliac disease. J Clin Pathol. 1990;43: 436. 10.1136/jcp.43.5.436 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Crabtree JE, O’Mahony S, Wyatt JI, Heatley R V, Vestey JP, Howdle PD, et al. Helicobacter pylori serology in patients with coeliac disease and dermatitis herpetiformis. J Clin Pathol. 1992;45: 597–600. 10.1136/jcp.45.7.597 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Feeley KM, Heneghan MA, Stevens FM, McCarthy CF. Lymphocytic gastritis and coeliac disease: evidence of a positive association. J Clin Pathol. 1998;51: 207–210. 10.1136/jcp.51.3.207 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Diamantti A, Maino C, Vazquez H, Pedreira S, Niveloni S, Smecuol E, et al. Celiac disease (CD), lymphocytic gastritis and Helicobacter pylori (HP) infection. A controlled study. Gastroenterology. 1998;114: A363. [Google Scholar]
  • 43.Diamanti A, Maino C, Niveloni S, Pedreira S, Vazquez H, Smecuol E, et al. Characterization of gastric mucosal lesions in patients with celiac disease: a prospective controlled study. Am J Gastroenterol. 1999;94: 1313–1319. 10.1111/j.1572-0241.1999.01082.x [DOI] [PubMed] [Google Scholar]
  • 44.Luzza F, Mancuso M, Imeneo M, Mesuraca L, Contaldo A, Giancotti L, et al. Helicobacter pylori infection in children with celiac disease: prevalence and clinicopathologic features. J Pediatr Gastroenterol Nutr. 1999;28: 143–146. 10.1097/00005176-199902000-00009 [DOI] [PubMed] [Google Scholar]
  • 45.Dettori I, Dore MP, Marras L, Nieddu S, Manca A, Massarelli G, et al. Is there anything to the reported association between Helicobacter pylori infection and celiac disease? Gut. 2001;49: A42–A42. [Google Scholar]
  • 46.Broide E, Sandbank J, Scapa E, Kimchi NA, Shapiro M, Lerner A. The immunohistochemistry profile of lymphocytic gastritis in celiac disease and Helicobacter pylori infection: interplay between infection and inflammation. Mediators Inflamm. 2007;2007. Broide E, Richter V, Shirin H. Is Helicobacter Pylori Chronic Infection Associated with the Severity of Celiac Disease in Children?. Gastroenterology. 2017. April 1;152(5):S245. 10.1155/2007/81838 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Józefczuk J, Mądry E, Nowak J, Walkowiak M, Łochocka K, Banasiewicz T, et al. Conflicting results of non-invasive methods for detection of Helicobacter pylori infection in children with celiac disease-a preliminary study. Acta Biochim Pol. 2016;63: 127–130. 10.18388/abp.2015_1088 [DOI] [PubMed] [Google Scholar]
  • 48.Dore MP, Salis R, Loria MF, Villanacci V, Bassotti G, Pes GM. Helicobacter pylori infection and occurrence of celiac disease in subjects HLA‐DQ 2/DQ 8 positive: A prospective study. Helicobacter. 2018;23: e12465. 10.1111/hel.12465 [DOI] [PubMed] [Google Scholar]
  • 49.Rostami-Nejad M, Villanacci V, Mashayakhi R, Molaei M, Bassotti G, Zojaji H, et al. Celiac disease and Hp infection association in Iran. Rev Esp Enfermedades Dig. 2009;101: 850–854. 10.4321/s1130-01082009001200004 [DOI] [PubMed] [Google Scholar]
  • 50.Rostami-Nejad M, Rostami K, Yamaoka Y, Mashayekhi R, Molaei M, Dabiri H, et al. Clinical and histological presentation of Helicobacter pylori and gluten related gastroenteropathy. Arch Iran Med. 2011;14: 115–119. [PMC free article] [PubMed] [Google Scholar]
  • 51.Bayrak NA, Tutar E, Volkan B, Sahin Akkelle B, Polat E, Kutluk G, et al. Helicobacter pylori infection in children with celiac disease: Multi‐center, cross‐sectional study. Helicobacter. 2020;25: e12691. 10.1111/hel.12691 [DOI] [PubMed] [Google Scholar]
  • 52.Bayrak NA, Volkan B. Helicobacter pylori infection in children with concurrent Celiac disease and type 1 Diabetes Mellitus. Dig Dis. 2021. 10.1159/000514276 [DOI] [PubMed] [Google Scholar]
  • 53.Mahdi BM. Immune response to Helicobacter pylori. Trends Helicobacter pylori Infect. 2014; 79. [Google Scholar]
  • 54.Yuan J, Li P, Tao J, Shi X, Hu B, Chen H, et al. H. pylori escape host immunoreaction through inhibiting ILK expression by VacA. Cell Mol Immunol. 2009;6: 191–197. 10.1038/cmi.2009.26 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Molinari M, Salio M, Galli C, Norais N, Rappuoli R, Lanzavecchia A, et al. Selective inhibition of Ii-dependent antigen presentation by Helicobacter pylori toxin VacA. J Exp Med. 1998;187: 135–140. 10.1084/jem.187.1.135 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Gebert B, Fischer W, Weiss E, Hoffmann R, Haas R. Helicobacter pylori vacuolating cytotoxin inhibits T lymphocyte activation. Science. 2003;301(5636): 1099–1102. 10.1126/science.1086871 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Endi Lanza Galvão

7 Jan 2021

PONE-D-20-31127

A Systematic Review and Meta-analysis for Association of Helicobacter pylori Colonization and Celiac Disease

PLOS ONE

Dear Dr. Besharat,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Your manuscript has been reviewed by two experts in the field and their comments are appended below. We believe the raised comments would improve the manuscript and may allow a revised version to be published in PLOS ONE.

Regarding my own concern, it is important that you revise the Introduction and Discussion sections in order to make the text more precise and concise. In the Methods section, the inclusion criteria comprise articles published until the “end of 2019”; authors should update their search to include more recent studies (if available), and the exact date of the updated search must be specified in the text. The first paragraph presented in “Quality and risk of bias assessment” should be reallocated to “Sources and search strategy”. It is unclear from the Methods section why the authors used a modified checklist of the Newcastle-Ottawa Scale (NOS) since there is a validated scale of NOS for case-control studies without the need for changes. What was modified in the used version? My last concern is related to the eligibility criteria: why cohort studies were not included?

The reviewers have constructively detailed other relevant issues. Please try to address all issues carefully in a revised manuscript.

Please submit your revised manuscript by Feb 21 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Endi Lanza Galvão

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

3. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Review of article:

A Systematic Review and Meta-analysis for Association of Helicobacter pylori

Colonization and Celiac Disease

1. Well-written manuscript fora n area with significant H. pylori infection prevalence.

2. A meta-analysis of a large number of studies and a total of 5241 patients and >13000 controls.

3. A clear method.

4. Introduction section:

- Please use a more recent and widely accepted reference. Ref no 2, 6 or 10 may be changed to for example: the ESsCD guideline 2019. Al-Toma et al. United European Gastroenterol J . 2019 Jun;7(5):583-613.

- The introduction can be shortened: for example the paragraph on the modes of presentation may be deleted or shortened. Also that on complications and diagnosis.

We need to focus on epidemiology, pathogenesis and relation with HP.

5. Discussion: This a very extensive section and difficult to comprehend. More than 2000 words.

This section should be more concise. The authors are trying to tackle all aspect of the topic. That is good; but the section is very difficult to read and in my opinion the data on earlier publications can be extremely shortened. All hypotheses , theories and mechanisms can be much summarized to give a clear message to the reader.

6. Conclusion in abstract and main body of manuscript: The suggestion that H. pylori has protective role towards CD needs to be somewhat modified. We do not know if the weak negative association may be regarded as protective. I would suggest saying ( The negative association might imply a mild protective role of HP against celiac disease.]

6. General note: CD is used widely as an abbreviation for celiac disease. Recently there is a trend to use CeD as an abbreviation to differentiate celiac from Crohn disease. Therefore, I would advise the authors to change to CeD.

7. The references are Ok. Some editing is needed due to software problems (can be done manually).

Reviewer #2: In the present systematic review and metaanalysis paper, the authors have described an association between colonisation of H pylori and Celiac disease. The authors have found a negative association between H pylori and Celiac disease. There a marked heterogeneity in the studies. Of 24 studies included, only 7 of them shows an association (inconsistency)

Comments:

1. Introduction: There reason and hypothesis of an association should be reflected in the introduction. The introduction is too lengthy and mostly unfocussed (the paragraph 2 may be deleted and paragraph 3 may be shorted).

2. Definition used in the study: The definition (reference) of celiac disease is not clear. Further how was a diagnosis of H pylori infection was made in the studies. Was the infection considered positive if one or two tests were positive.

3. Who were the controls?

4. Of 7 studies showing an association between celiac disease and IHC, the basis of diagnosis H pylori in 6 of them was IHC. Is this also a factor that can explain the heterogeneity.

5. Discussion is very exhaustive and unfocussed. This should shortened substantially.

Minor:

Legends may be written separately, at the end of the manuscript.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Dr Govind Makharia

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Mar 3;16(3):e0241156. doi: 10.1371/journal.pone.0241156.r002

Author response to Decision Letter 0


4 Feb 2021

3-Feb-2021

Dear Prof. Joerg Heber,

The editor in chief of the journal of PLOS One,

We appreciate the time and efforts of the editor and reviewers in reviewing this manuscript. We revised the manuscript (ID: No. PONE-D-20-31127, entitled "A Systematic Review and Meta-analysis for Association of Helicobacter pylori Colonization and Celiac Disease") and corrected all points mentioned by the journal’s reviewers. All changes based on the editor and reviewer’s comments and questions are marked with the highlighted tracked changes in the “track-changed version” of the revised manuscript text. A “clean version” of the revised manuscript has also been prepared. Besides, in the following lines, we answered the editor and reviewer’s questions, marked by a bullet.

The editor’s comment:

Regarding my own concern, it is important that you revise the Introduction and Discussion sections in order to make the text more precise and concise.

• Thank you for the suggestion. Based on your concern, as well as reviewers’ comments, both Introduction and Discussion sections were revised. We try to concise the sections. In addition to summarizing, we tried to write the text in a coherent and integrated manner. Some parts in the introduction related to the modes of presentation and diagnosis of celiac disease were deleted. Furthermore, some parts of the discussion were transferred to the introduction.

In the Methods section, the inclusion criteria comprise articles published until the “end of 2019”; authors should update their search to include more recent studies (if available), and the exact date of the updated search must be specified in the text.

• Thank you for your suggestion that improves our result. We updated our systematic search until 28 February 2021. With the new syntax, 59 articles were added and after the screen step, five of them were selected for full-text evaluation. Finally, two articles (with 760 cases and 2565 control population) were added to the systematic review and meta-analysis part. Both new papers belonged to Turkey. According to the new results, all figures were also updated.

The first paragraph presented in “Quality and risk of bias assessment” should be reallocated to “Sources and search strategy”.

• We greatly appreciate your suggestion. The mentioned first paragraph reallocated to the “Sources and search strategy” part.

It is unclear from the Methods section why the authors used a modified checklist of the Newcastle-Ottawa Scale (NOS) since there is a validated scale of NOS for case-control studies without the need for changes. What was modified in the used version?

• Thank you for your very detailed point. We intended to make changes to the standard form of NOS, if necessary, for evaluation of a particular type of cohort studies, but in the end, there was no need to change. So we used the standard form. But (unfortunately), we forgot to delete the “modified” word from our first protocol plan and the text of the manuscript. As a result and based on your insightful comment, we deleted the word “modified” (which was written wrongly) before the name of the Newcastle-Ottawa Scale (NOS) form.

My last concern is related to the eligibility criteria: why cohort studies were not included?

• We apologize for the ambiguity. At first, we wanted to evaluate any case-control and all type of cohort study. But after evaluation of the full text of studies, no cohort study passed our inclusion criteria based on our aims. So that, we removed the name of “the cohort study type” from the method section. However, to avoid ambiguity and also based on your comment, we have again added more explanation about not finding cohort studies in the methods and result parts. We added the following sentence to the method part: “Case-control, cross-sectional, suitable cohort, and brief-report studies that contain evidence about the relationship between H. pylori and CD”. Furthermore, we added the following sentence to the result part: “In the end, there was no suitable cohort study in the included studies”. Thank you for your question.

The answers to the comments of reviewer 1:

1. Well-written manuscript for an area with significant H. pylori infection prevalence. 2. A meta-analysis of a large number of studies and a total of 5241 patients and >13000 controls. 3. A clear method.

• Thank you. We greatly appreciate the reviewer’s efforts to carefully review the paper.

4. Introduction section: Please use a more recent and widely accepted reference. Ref no 2, 6 or 10 may be changed to for example: the ESsCD guideline 2019. Al-Toma et al. United European Gastroenterol J . 2019 Jun;7(5):583-613.

• We greatly appreciate the reviewer’s efforts to carefully review the paper. According to the opinion of the reviewer, we used the mentioned reference (ESsCD guideline) and added it to the introduction of the manuscript.

The introduction can be shortened: for example, the paragraph on the modes of presentation may be deleted or shortened, also that on complications and diagnosis. We need to focus on epidemiology, pathogenesis and relation with HP.

• We greatly appreciate the reviewer’s efforts to carefully review the paper. According to the opinion of the reviewer, we did the following changes in the introduction of the manuscript. We try to concise the sections. In addition to summarizing, we tried to write the text in a coherent and integrated manner. Some parts in the introduction related to the modes of presentation and diagnosis of celiac disease (CeD) were deleted. We also added information about the prevalence of CeD in the world (epidemiology information) and the relation of CeD with H. pylori and its possible mechanisms to this part.

5. Discussion: This is a very extensive section and difficult to comprehend, more than 2000 words. This section should be more concise. The authors are trying to tackle all aspect of the topic. That is good; but the section is very difficult to read and in my opinion the data on earlier publications can be extremely shortened. All hypotheses, theories and mechanisms can be much summarized to give a clear message to the reader.

• We appreciate the reviewer’s comment. We tried to concise the sections. In addition to summarizing, we tried to write the text in a coherent and integrated manner. All hypotheses, theories, and mechanisms were summarized at first and transferred to the introduction part, as were more related to this part (based on the opinion of another reviewer). All changes in this part are marked with the highlighted tracked changes.

6. Conclusion in abstract and main body of manuscript: The suggestion that H. pylori has protective role towards CD needs to be somewhat modified. We do not know if the weak negative association may be regarded as protective. I would suggest saying (The negative association might imply a mild protective role of H. pylori against celiac disease).

• Thank you for the suggestion. We considered your comment and used the “mild” term for the negative association and the protective possibility.

6. General note: CD is used widely as an abbreviation for celiac disease. Recently there is a trend to use CeD as an abbreviation to differentiate celiac from Crohn’s disease. Therefore, I would advise the authors to change to CeD.

• According to the insightful suggestion of the reviewer, we updated the abbreviation of “celiac disease” from “CD” to “CeD”, to differentiate celiac from Crohn’s disease and make the text smoother for the readers.

7. The references are Ok. Some editing is needed due to software problems (can be done manually).

• After performing the plain text, the references part was checked, revised, and corrected.

The answers to the comments of reviewer 2:

In the present systematic review and metaanalysis paper, the authors have described an association between colonisation of H pylori and Celiac disease. The authors have found a negative association between H. pylori and Celiac disease. There are a marked heterogeneity in the studies. Of 24 studies included, only 7 of them shows an association (inconsistency).

• Thank you, we tried to evaluate any possible source for the heterogeneity. We also revised our conclusion with the following sentence: The negative association might imply a mild protective role of H. pylori against celiac disease.

Comments:

1. Introduction: There reason and hypothesis of an association should be reflected in the introduction. The introduction is too lengthy and mostly unfocussed (the paragraph 2 may be deleted and paragraph 3 may be shorted).

• We greatly appreciate the reviewer’s efforts to carefully review the paper. According to the opinion of the referee, we tried to concise the sections and write the text in a coherent and integrated manner. In addition to summarizing, we deleted the mentioned paragraphs. We transferred some part of the discussion (reasons and hypotheses) to the introduction part. All changes in this part are marked with the highlighted tracked changes.

2. Definition used in the study: The definition (reference) of celiac disease is not clear. Further how was a diagnosis of H. pylori infection was made in the studies. Was the infection considered positive if one or two tests were positive?

• Thank you for the suggestion. We added the definition section to the method parts and tried to explain the case and control groups. CeD patients were defined if they were positive for CeD-specific antibodies (comprise autoantibodies against TG2, including endomysial antibodies (EMA), and antibodies against deamidated forms of gliadin peptides (DGP)), associated with biopsy-proven histopathology or positive for genetic tests including HLA-DQ2 or HLA-DQ8 haplotypes in the primary studies.

• We considered H. pylori infection in the study (case/control) population if one of the following tests was positive: urea breath test (UBT), rapid urease test (RUT), culture, enzyme-linked immunosorbent assay (ELISA), histology, immunohistochemistry (IHC), and Polymerase chain reaction (PCR) methods. However, after data extraction, as some tests were used only one or two times in the included studies, we combined similar tests for subgroup analysis to perform statistical analysis.

3. Who were the controls?

• Based on the definitions in the primary studies, controls consisted of those apparently healthy people, or celiac disease was ruled out through negative serology/biopsy in the control population. We added this definition to the method part.

4. Of 7 studies showing an association between celiac disease and IHC (H. pylori), the basis of diagnosis H. pylori in 6 of them was IHC. Is this also a factor that can explain the heterogeneity?

• Thank you for the insightful comment. We evaluated the included studies based on the detection method of H. pylori by subgrouping to analyze the source of heterogeneity. Among 26 studies, 19 studies used IHC for the detection of H. pylori, among them seven studies (36.8%) had an association between CeD and H. pylori. Otherwise, the other seven studies used some other methods such as RUT and among them, two studies (28.5%) showed the mentioned association. Therefore, it seems that this factor could not play role in heterogeneity (the difference is not statistical).

5. Discussion is very exhaustive and unfocussed. This should be shortened substantially.

• Thank you for the comment. Regarding the comments of both reviewers, we summarized the discussion section. We transferred all hypotheses, and mechanisms that supported both sides of the association to the introduction. We tried to focus on the main result of the present study and discuss more related to the source of heterogeneity and methodology of the included studies.

Minor:

Legends may be written separately, at the end of the manuscript.

• Thank you for the suggestion. According to the guideline of the journal, all legends related to Figures and Tables should be placed in the proper location of the text of the manuscript. Therefore, we stick to the journal guideline.

Best.

Attachment

Submitted filename: Answer to reviewers_PONE-D-20-31127.docx

Decision Letter 1

Endi Lanza Galvão

15 Feb 2021

A Systematic Review and Meta-analysis for Association of Helicobacter pylori Colonization and Celiac Disease

PONE-D-20-31127R1

Dear Dr. Besharat,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Endi Lanza Galvão

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: (No Response)

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #2: n the present systematic review and metaanalysis paper, the authors have described an association between colonisation of H pylori and Celiac disease.

Thank you so very much for responding to our comments

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Govind K Makharia

Acceptance letter

Endi Lanza Galvão

18 Feb 2021

PONE-D-20-31127R1

A Systematic Review and Meta-analysis for Association of Helicobacter pylori Colonization and Celiac Disease

Dear Dr. Besharat:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Endi Lanza Galvão

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Checklist

    (DOC)

    S1 File

    (DOCX)

    Attachment

    Submitted filename: Answer to reviewers_PONE-D-20-31127.docx

    Data Availability Statement

    The data underlying the results presented in the study are available from supporting information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES